---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-058003"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:15:36.140012+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q1 net loss $64.8M ($0.49/sh); revenue $14.8M up 10.4% YoY

## Summary
- Net loss of $64.8M ($0.49/sh) vs $30.3M loss ($0.39/sh) in Q1 2023; includes $28M non-cash loss on debt extinguishment.
- Total net revenue $14.8M, up 10.4% YoY, driven by DEXTENZA product sales.
- Cash and equivalents $482.9M; Feb 2024 private placement raised $325M; cash runway expected into 2028.
- Phase 3 SOL-1 wet AMD trial randomization started April 2024; site activation progressing under FDA SPA.
- Pravin Dugel appointed Exec Chairman, President & CEO; Investor Day set for June 13, 2024.

## SEC filing metadata
- accession: 0001104659-24-058003
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465924058003/0001104659-24-058003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465924058003/tm2413661d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-058003
- JSON: https://secwatch.observer/filing/0001104659-24-058003.json
- Plain text: https://secwatch.observer/filing/0001104659-24-058003.txt

## Key facts
- Earnings Releases
  OCULAR THERAPEUTIX, INC reported first quarter ended March 31, 2024 results: revenue $14.8 million, net income $(64.8) million, EPS $(0.49) per share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $14.8 million
  - Net income: $(64.8) million
  - EPS: $(0.49) per share
  - Result: reported results
  source text: Company believes that its current cash balance is sufficient to support its planned expenses, obligations, and capital expenditure requirements into 2028. Total net revenue was $14.8 million for the first quarter of 2024, a 10.4% increase over total net revenue of $13.4 million in the comparable period in 2023, driven by increased DEXTENZA sales. Total net revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924058003/0001104659-24-058003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.